StockData
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. (NRXP) KPIs and segments

NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.45+0.30 (+13.95%)

Close on Nov 17, 2026Market cap $106.08MP/E –Yield –

KPIs & segments

Operating metrics and segments that drive NRX Pharmaceuticals's business

NRX Pharmaceuticals's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Add to chartMetric
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Therapy($M)
0.870.760.700.15
Procedures($M)
0.230.310.280.09
Dura Segment($M)
0.100.08-0.100.02
NRx Segment($M)
-6.60-4.83-4.52-4.04
Dura Segment($M)
0.110.09-0.100.02
NRx Segment($M)
-16.6-1.520.46-5.91

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2026-08-14.

See a number that looks wrong?